Published in Proc Natl Acad Sci U S A on January 15, 1993
CAR-T Cell Immunotherapy for Advanced Lung Cancer | NCT03330834
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood (2009) 9.24
Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther (2010) 9.13
Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med (2014) 8.21
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood (2010) 7.25
Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther (2009) 6.91
CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest (2011) 6.38
Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol (2009) 5.33
Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol (2014) 3.94
Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood (2010) 3.57
Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood (2013) 3.45
The basic principles of chimeric antigen receptor design. Cancer Discov (2013) 3.28
CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood (2012) 2.97
Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. J Immunother (2009) 2.35
Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia (2010) 2.22
Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol (2013) 1.91
Treatment of advanced leukemia in mice with mRNA engineered T cells. Hum Gene Ther (2011) 1.87
Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clin Cancer Res (2013) 1.85
Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J (2014) 1.64
B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin Cancer Res (2013) 1.60
Differentiation of naive cord-blood T cells into CD19-specific cytolytic effectors for posttransplantation adoptive immunotherapy. Blood (2005) 1.57
CD3 delta deficiency arrests development of the alpha beta but not the gamma delta T cell lineage. EMBO J (1997) 1.54
Engineered T cells: the promise and challenges of cancer immunotherapy. Nat Rev Cancer (2016) 1.51
Chimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challenges. J Hematol Oncol (2013) 1.46
In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia. PLoS One (2016) 1.44
Fifteen years of gene therapy based on chimeric antigen receptors: "are we nearly there yet?". Hum Gene Ther (2009) 1.44
4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies. Hum Gene Ther (2010) 1.40
Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions. J Gene Med (2012) 1.40
Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease. J Clin Oncol (2016) 1.39
The future is now: chimeric antigen receptors as new targeted therapies for childhood cancer. Clin Cancer Res (2012) 1.37
Monitoring the efficacy of adoptively transferred prostate cancer-targeted human T lymphocytes with PET and bioluminescence imaging. J Nucl Med (2008) 1.35
Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain. J Exp Med (1993) 1.35
Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia. Mol Ther (2013) 1.33
Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells. Immunol Rev (2014) 1.33
Optimization of the PiggyBac transposon system for the sustained genetic modification of human T lymphocytes. J Immunother (2009) 1.32
PiggyBac-mediated cancer immunotherapy using EBV-specific cytotoxic T-cells expressing HER2-specific chimeric antigen receptor. Mol Ther (2011) 1.32
Chimeric antigen receptor-engineered T cells for immunotherapy of cancer. J Biomed Biotechnol (2010) 1.30
Immunotherapy of human cancers using gene modified T lymphocytes. Curr Gene Ther (2009) 1.29
Infusing CD19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stem-cell transplantation for advanced B-lymphoid malignancies. Hum Gene Ther (2012) 1.29
T cells redirected to EphA2 for the immunotherapy of glioblastoma. Mol Ther (2012) 1.21
Regimen-specific effects of RNA-modified chimeric antigen receptor T cells in mice with advanced leukemia. Hum Gene Ther (2013) 1.21
CAR therapy: the CD19 paradigm. J Clin Invest (2015) 1.20
Antitumor activity of cytotoxic T lymphocytes engineered to target vascular endothelial growth factor receptors. Proc Natl Acad Sci U S A (2002) 1.20
Toxicity management for patients receiving novel T-cell engaging therapies. Curr Opin Pediatr (2014) 1.19
TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy. Mol Ther Nucleic Acids (2013) 1.16
2B4 (CD244) signaling by recombinant antigen-specific chimeric receptors costimulates natural killer cell activation to leukemia and neuroblastoma cells. Clin Cancer Res (2009) 1.15
A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor. Cancer Res (2012) 1.15
Considerations for the clinical application of chimeric antigen receptor T cells: observations from a recombinant DNA Advisory Committee Symposium held June 15, 2010. Cancer Res (2011) 1.15
Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice. Proc Natl Acad Sci U S A (2005) 1.14
A new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19. Immunol Rev (2014) 1.14
Combining CD19 redirection and alloanergization to generate tumor-specific human T cells for allogeneic cell therapy of B-cell malignancies. Cancer Res (2010) 1.10
The pharmacology of second-generation chimeric antigen receptors. Nat Rev Drug Discov (2015) 1.09
Novel immunotherapies in lymphoid malignancies. Nat Rev Clin Oncol (2015) 1.09
Toxicities of chimeric antigen receptor T cells: recognition and management. Blood (2016) 1.07
Cancer vaccines. BMJ (2015) 1.07
Targeting of T lymphocytes to melanoma cells through chimeric anti-GD3 immunoglobulin T-cell receptors. Neoplasia (2001) 1.06
Autologous and allogeneic cellular therapies for high-risk pediatric solid tumors. Pediatr Clin North Am (2010) 1.04
Anti-tumor potential of type-I NKT cells against CD1d-positive and CD1d-negative tumors in humans. Clin Immunol (2010) 1.04
IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo. Oncoimmunology (2015) 1.04
Cancer immunotherapy: harnessing the immune system to battle cancer. J Clin Invest (2015) 1.04
Immunotherapy approaches for malignant glioma from 2007 to 2009. Curr Neurol Neurosci Rep (2010) 1.04
Prospects for gene-engineered T cell immunotherapy for solid cancers. Nat Med (2016) 1.03
T-cell and natural killer cell therapies for hematologic malignancies after hematopoietic stem cell transplantation: enhancing the graft-versus-leukemia effect. Haematologica (2015) 1.02
A high molecular weight melanoma-associated antigen-specific chimeric antigen receptor redirects lymphocytes to target human melanomas. Cancer Res (2010) 1.02
Tumor evasion from T cell surveillance. J Biomed Biotechnol (2011) 1.01
OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4(+) T cells. Oncoimmunology (2012) 1.01
T-cell immunotherapy: looking forward. Mol Ther (2014) 1.00
Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells. Proc Natl Acad Sci U S A (1994) 0.99
Antibody, T-cell and dendritic cell immunotherapy for malignant brain tumors. Future Oncol (2013) 0.97
Adoptive T cell therapy of cancer. Curr Opin Immunol (2009) 0.97
A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors. Cancer Res (2016) 0.96
Hematopoietic stem cells for cancer immunotherapy. Immunol Rev (2014) 0.95
Simplified process for the production of anti-CD19-CAR-engineered T cells. Cytotherapy (2013) 0.95
Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review. Mol Cancer (2015) 0.94
Interleukin-7 mediates selective expansion of tumor-redirected cytotoxic T lymphocytes (CTLs) without enhancement of regulatory T-cell inhibition. Clin Cancer Res (2013) 0.94
Toxicity and management in CAR T-cell therapy. Mol Ther Oncolytics (2016) 0.93
A sensitivity scale for targeting T cells with chimeric antigen receptors (CARs) and bispecific T-cell Engagers (BiTEs). Oncoimmunology (2012) 0.91
Cellular immunotherapy for high-grade glioma. Immunotherapy (2011) 0.91
Adoptive cell therapies for glioblastoma. Front Oncol (2013) 0.90
Emerging Opportunities and Challenges in Cancer Immunotherapy. Clin Cancer Res (2016) 0.89
Seatbelts in CAR therapy: How Safe Are CARS? Pharmaceuticals (Basel) (2015) 0.89
T lymphocytes redirected against the chondroitin sulfate proteoglycan-4 control the growth of multiple solid tumors both in vitro and in vivo. Clin Cancer Res (2013) 0.89
Genetic modification of human T lymphocytes for the treatment of hematologic malignancies. Haematologica (2012) 0.88
CD28 co-stimulation via tumour-specific chimaeric receptors induces an incomplete activation response in Epstein-Barr virus-specific effector memory T cells. Clin Exp Immunol (2006) 0.88
Combining T-cell immunotherapy and anti-androgen therapy for prostate cancer. Prostate Cancer Prostatic Dis (2013) 0.87
Elimination of progressive mammary cancer by repeated administrations of chimeric antigen receptor-modified T cells. Mol Ther (2014) 0.87
Immunotherapy targeting EBV-expressing lymphoproliferative diseases. Best Pract Res Clin Haematol (2008) 0.86
Design of T-cell receptor libraries with diverse binding properties to examine adoptive T-cell responses. Gene Ther (2012) 0.86
Optimization manufacture of virus- and tumor-specific T cells. Stem Cells Int (2011) 0.86
Generation of Potent T-cell Immunotherapy for Cancer Using DAP12-Based, Multichain, Chimeric Immunoreceptors. Cancer Immunol Res (2015) 0.86
Targeting T cells with bispecific antibodies for cancer therapy. BioDrugs (2011) 0.85
Treatment of lymphoma with adoptively transferred T cells. Expert Opin Biol Ther (2009) 0.85
Genetically modified T cells in cancer therapy: opportunities and challenges. Dis Model Mech (2015) 0.85
The human application of gene therapy to re-program T-cell specificity using chimeric antigen receptors. Chin J Cancer (2014) 0.85
A new hope in immunotherapy for malignant gliomas: adoptive T cell transfer therapy. J Immunol Res (2014) 0.85
Animal models for IgE-meditated cancer immunotherapy. Cancer Immunol Immunother (2011) 0.85
The Evolution of T-cell Therapies for Solid Malignancies. Clin Cancer Res (2015) 0.84
Adoptive immunotherapy for hematological malignancies using T cells gene-modified to express tumor antigen-specific receptors. Pharmaceuticals (Basel) (2014) 0.84
Engineering T cell function using chimeric antigen receptors identified using a DNA library approach. PLoS One (2013) 0.84
Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods (1983) 114.35
Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion. Eur J Immunol (1976) 30.70
A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science (1986) 8.07
Fc receptors. Annu Rev Immunol (1991) 7.92
Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc Natl Acad Sci U S A (1988) 6.14
The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways. Cell (1991) 6.13
Single-chain antigen-binding proteins. Science (1988) 5.29
Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci U S A (1989) 4.63
Structure and function of human and murine receptors for IgG. Annu Rev Immunol (1988) 3.90
Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science (1984) 3.08
Sequence requirements for induction of cytolysis by the T cell antigen/Fc receptor zeta chain. Cell (1992) 2.69
Cellular immunity to HIV activated by CD4 fused to T cell or Fc receptor polypeptides. Cell (1991) 2.45
T-cell and basophil activation through the cytoplasmic tail of T-cell-receptor zeta family proteins. Proc Natl Acad Sci U S A (1991) 2.32
Characterization and expression of the gene for the human Fc receptor gamma subunit. Definition of a new gene family. J Biol Chem (1990) 2.17
Family of disulphide-linked dimers containing the zeta and eta chains of the T-cell receptor and the gamma chain of Fc receptors. Nature (1990) 2.14
Transmission and expression of a specific pair of rearranged immunoglobulin mu and kappa genes in a transgenic mouse line. Nature (1985) 2.08
Expression of a hybrid immunoglobulin-T cell receptor protein in transgenic mice. Cell (1989) 1.66
Karnofsky Memorial Lecture. The immunotherapy and gene therapy of cancer. J Clin Oncol (1992) 1.64
Monoclonal antibodies in diagnosis and therapy. Science (1991) 1.63
Role of the zeta chain in the expression of the T cell antigen receptor: genetic reconstitution studies. EMBO J (1989) 1.62
In vivo tumor targeting of a recombinant single-chain antigen-binding protein. J Natl Cancer Inst (1990) 1.61
Signal transduction by Fc gamma RIII (CD16) is mediated through the gamma chain. J Exp Med (1992) 1.58
Structural similarity between Fc receptors and T cell receptors. Expression of the gamma-subunit of Fc epsilon RI in human T cells, natural killer cells and thymocytes. J Immunol (1991) 1.44
Generation of effector T cells expressing chimeric T cell receptor with antibody type-specificity. Transplant Proc (1989) 1.36
Cytotoxic T lymphocyte hybridomas that mediate specific tumor-cell lysis in vitro. Proc Natl Acad Sci U S A (1981) 1.36
Chimeric immunoglobulin-T cell receptor proteins form functional receptors: implications for T cell receptor complex formation and activation. Cell (1990) 1.15
Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions. Biochem Biophys Res Commun (1987) 1.12
Differential signal transduction via T-cell receptor CD3 zeta 2, CD3 zeta-eta, and CD3 eta 2 isoforms. Proc Natl Acad Sci U S A (1991) 1.07
Association of the human Fc epsilon RI gamma subunit with novel cell surface polypeptides. J Immunol (1992) 1.01
Monoclonal antibody therapy of lymphoid malignancy. Cancer Surv (1985) 0.93
Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci U S A (1989) 4.63
A complete mapping of the proteins in the small ribosomal subunit of Escherichia coli. Science (1987) 2.43
Human papillomavirus type-16-related DNA in genital Bowen's disease and in Bowenoid papulosis. Int J Cancer (1983) 2.30
Generation of hybridomas secreting murine reaginic antibodies of anti-DNP specificity. J Immunol (1980) 2.14
Subclassification of alpha 1-adrenoceptor recognition sites by urapidil derivatives and other selective antagonists. Br J Pharmacol (1989) 2.00
Expression of human bone morphogenetic proteins-2 or -4 in murine mesenchymal progenitor C3H10T1/2 cells induces differentiation into distinct mesenchymal cell lineages. DNA Cell Biol (1993) 1.81
European course on HPV associated pathology: guidelines for primary care physicians for the diagnosis and management of anogenital warts. Sex Transm Infect (2000) 1.80
Does increased endogenous formation of N-nitroso compounds in the human colon explain the association between red meat and colon cancer? Carcinogenesis (1996) 1.65
Neonatal supplementation of processed supernatant from Lactobacillus rhamnosus GG improves allergic airway inflammation in mice later in life. Clin Exp Allergy (2013) 1.50
Inhaled salmeterol and fluticasone: a study comparing monotherapy and combination therapy in asthma. Ann Allergy Asthma Immunol (1999) 1.46
Specific cleavage of ribosomal RNA caused by alpha sarcin. Nucleic Acids Res (1977) 1.45
Optimization of isolated hyperthermic limb perfusion. World J Surg (1993) 1.44
Inducibility of human beta-interferon gene in mouse L-cell clones. Nature (1982) 1.43
Papillomavirus infection of the anogenital region: correlation between histology, clinical picture, and virus type. Proposal of a new nomenclature. J Invest Dermatol (1985) 1.42
Promoter and enhancer elements in the rearranged alpha chain gene of the human T cell receptor. EMBO J (1987) 1.40
Biliary complications related to laparoscopic cholecystectomies: radiologic diagnosis and management. Surg Laparosc Endosc (1992) 1.39
In vitro and in vivo induction of effector T cells mediating DTH responses to a protein and a synthetic polypeptide antigen. Cell Immunol (1979) 1.38
Generation of effector T cells expressing chimeric T cell receptor with antibody type-specificity. Transplant Proc (1989) 1.36
Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain. J Exp Med (1993) 1.35
The structure of a thirty-six kilobase region of the human chromosome including the fibroblast interferon gene IFN-beta. Nucleic Acids Res (1981) 1.33
Positions of proteins S6, S11 and S15 in the 30 S ribosomal subunit of Escherichia coli. J Mol Biol (1981) 1.31
Correlation between human papillomavirus (HPV) type and histology of warts. J Invest Dermatol (1982) 1.25
Bowenoid papulosis. Presence of human papillomavirus (HPV) structural antigens and of HPV 16-related DNA sequences. Arch Dermatol (1985) 1.24
A long-term follow-up study of schizophrenia: psychiatric course of illness and prognosis. Acta Psychiatr Scand (1975) 1.24
Purification and chemical characterization of beta-trace protein from human cerebrospinal fluid: its identification as prostaglandin D synthase. J Neurochem (1993) 1.22
Bmp-2 downstream targets in mesenchymal development identified by subtractive cloning from recombinant mesenchymal progenitors (C3H10T1/2). Dev Dyn (1998) 1.21
Phospholipid-hydroperoxide glutathione peroxidase. Genomic DNA, cDNA, and deduced amino acid sequence. J Biol Chem (1994) 1.20
European guideline for the management of anogenital warts. Int J STD AIDS (2001) 1.18
Analysis of benign and malignant urogenital tumors for human papillomavirus infection by labelling cellular DNA. Med Microbiol Immunol (1986) 1.17
Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol (2000) 1.14
Effects of maternal deprivation on the ACTH stress response in the infant rat. Neuroendocrinology (1993) 1.14
Functional expression of chimeric receptor genes in human T cells. J Immunol Methods (2001) 1.12
Tyrosine phosphorylation of insulin receptor substrate-1 in vivo depends upon the presence of its pleckstrin homology region. J Biol Chem (1995) 1.12
Polyriboadenylate polymerase solubilized from rat liver mitochondria. Biochem Biophys Res Commun (1972) 1.10
The concept of basic symptoms in schizophrenic and schizoaffective psychoses. Recenti Prog Med (1989) 1.10
Enhancement of translational efficiency by the Escherichia coli atpE translational initiation region: its fusion with two human genes. Gene (1986) 1.10
The T-body approach: potential for cancer immunotherapy. Springer Semin Immunopathol (1996) 1.10
Characterization of human papillomavirus 3 in warts of a renal allograft patient. J Invest Dermatol (1979) 1.08
Thyroid-dependent alterations of myocardial adrenoceptors and adrenoceptor-mediated responses in the rat. Naunyn Schmiedebergs Arch Pharmacol (1985) 1.07
BMP signaling pathways in cartilage and bone formation. Crit Rev Eukaryot Gene Expr (2001) 1.05
Molecular cloning of two new HPV types (HPV 37 and HPV 38) from a keratoacanthoma and a malignant melanoma. Int J Cancer (1986) 1.04
Longitudinal studies of schizophrenic patients. Schizophr Bull (1980) 1.04
Radioligand binding studies of alpha 1-adrenoceptor subtypes in rat heart. Br J Pharmacol (1994) 1.02
Characterization of a ts beta' mutant RNA polymerase of Escherichia coli. Mol Gen Genet (1976) 1.01
Targeting of T lymphocytes to Neu/HER2-expressing cells using chimeric single chain Fv receptors. J Immunol (1993) 1.00
Circadian rhythm of tryptophan, serotonin, melatonin, and pituitary hormones in schizophrenia. Biol Psychiatry (1994) 0.99
Systemic treatment of condylomata acuminata with recombinant interferon-alpha-2a: low-dose superior to the high-dose regimen. Chemotherapy (1986) 0.98
Functional studies on alpha 1-adrenoceptor subtypes mediating inotropic effects in rat right ventricle. Br J Pharmacol (1994) 0.95
The bone morphogenetic protein 2 signaling mediator Smad1 participates predominantly in osteogenic and not in chondrogenic differentiation in mesenchymal progenitors C3H10T1/2. J Bone Miner Res (2000) 0.95
Altered energy metabolism in anorexia nervosa. Psychoneuroendocrinology (2001) 0.95
Dopamine D(3) receptors and salt-dependent hypertension. J Am Soc Nephrol (2001) 0.95
Epidemiology of herpes simplex virus types 1 and 2 in Germany: what has changed? Med Microbiol Immunol (2003) 0.95
Developmental expression analysis of murine autotaxin (ATX). Mech Dev (1999) 0.94
Activation of T and B lymphocytes in vitro. V. Cellular locus, metabolism and genetics of induction, and production of the allogeneic effect factor. J Immunol (1977) 0.94
Structural convergence in the active sites of a family of catalytic antibodies. Science (1997) 0.94
Multicentre, phase II trial on the safety and efficacy of topical tacrolimus ointment for the treatment of lichen sclerosus. Br J Dermatol (2006) 0.93
Spin-lattice relaxation (T1) times of cerebral white matter in multiple sclerosis. Magn Reson Med (1986) 0.93
[Schizophrenia. Clinical course and social psychiatric long term examinations of schizophrenic patients hospitalized in Bonn from 1945-1959]. Monogr Gesamtgeb Psychiatr Psychiatry Ser (1979) 0.93
DNA microarray technology and its applications in dermatology. Exp Dermatol (2004) 0.93
Successful treatment of condylomata acuminata and bowenoid papulosis with subcutaneous injections of low-dose recombinant interferon-alpha. Arch Dermatol (1986) 0.93
Could inflammatory arthritis be triggered by progenitor cells in the joints? Ann Rheum Dis (2002) 0.92
Alpha 1-adrenoceptors: the ability of various agonists and antagonists to discriminate between two distinct [3H]prazosin binding sites. J Pharm Pharmacol (1989) 0.92
Parathyroid hormone enhances early and suppresses late stages of osteogenic and chondrogenic development in a BMP-dependent mesenchymal differentiation system (C3H10T1/2). J Bone Miner Res (1997) 0.92
[Sensory disorders in schizophrenia]. Arch Psychiatr Nervenkr (1970) (1972) 0.92
WISH-PC2: a unique xenograft model of human prostatic small cell carcinoma. Cancer Res (2000) 0.91
Psychopathology of basic stages of schizophrenia in view of formal thought disturbances. Psychopathology (1985) 0.91
Basic symptoms in schizophrenic and affective psychoses. Psychopathology (1989) 0.91
Activation of c-Jun NH2-terminal kinase/stress-activated protein kinase (JNK/SAPK) is critical for hypoxia-induced apoptosis of human malignant melanoma. Cell Growth Differ (2001) 0.91
Transfer of chimeric receptor gene made of variable regions of tumor-specific antibody confers anticarbohydrate specificity on T cells. Cancer Gene Ther (1999) 0.90
Serum amino acids, central monoamines, and hormones in drug-naive, drug-free, and neuroleptic-treated schizophrenic patients and healthy subjects. Psychiatry Res (1990) 0.90
Harnessing Syk family tyrosine kinases as signaling domains for chimeric single chain of the variable domain receptors: optimal design for T cell activation. J Immunol (1998) 0.89
Reduction of cardiac outward currents by alpha-1 adrenoceptor stimulation: a subtype-specific effect? J Pharmacol Exp Ther (1991) 0.89
Synaptic transmission is impaired prior to plaque formation in amyloid precursor protein-overexpressing mice without altering behaviorally-correlated sharp wave-ripple complexes. Neuroscience (2009) 0.89
Seroepidemiologic studies of bovine papillomavirus infections. J Natl Cancer Inst (1979) 0.88
Differences in the biochemical properties of esterolytic antibodies correlate with structural diversity. Mol Immunol (1994) 0.88
Culture of primary human gingival fibroblasts on biodegradable membranes. Biomaterials (2002) 0.88
Effects of thyroid hormone deficiency on pre- and postsynaptic noradrenergic mechanisms in the rat cerebral cortex. Arch Int Pharmacodyn Ther (1980) 0.87
[Long-term course of schizophrenic psychoses. Joint results of two studies]. Nervenarzt (1976) 0.87
The production of monoclonal antibodies against glomerular and other antigens of the human nephron. Ren Physiol (1981) 0.87
Dopamine receptor 3 (D3) knockout mice show regular emotional behaviour. Pharmacol Res (2008) 0.87
Positions of proteins S10, S11 and S12 in the 30 S ribosomal subunit of Escherichia coli. J Mol Biol (1979) 0.86
Demography, symptomatology, and course of disease in ambulatory zoster patients. A physician-based survey in Germany. Intervirology (1998) 0.86
Effect of oral aromatic retinoid (Ro 10-9359) on human papilloma virus-2-induced common warts. Dermatologica (1983) 0.85
B-cell chronic lymphocytic leukemia associated with high serum IGE levels and pruriginous skin lesions: successful therapy with IFN-alpha 2b after failure on IFN-gamma. Dermatology (1996) 0.85
Double dissociation of the effects of haloperidol and the dopamine D3 receptor antagonist ABT-127 on acquisition vs. expression of cocaine-conditioned activity in rats. J Pharmacol Exp Ther (2010) 0.85
Treatment of atypical leishmaniasis with interferon gamma resulting in progression of Kaposi's sarcoma in an AIDS patient. Clin Investig (1994) 0.84
Early self-experienced neuropsychological deficits and subsequent schizophrenic diseases: an 8-year average follow-up prospective study. Acta Psychiatr Scand (1997) 0.84
P/Q-type calcium channel modulators. Br J Pharmacol (2012) 0.84
Antibodies against linear and conformational epitopes of the human papillomavirus (HPV) type 16 E6 and E7 oncoproteins in sera of cervical cancer patients. Arch Virol (1994) 0.84
Acanthosis nigricans maligna. Clinical and virological investigations. Dermatologica (1984) 0.84
A β-amyloid oligomer directly modulates P/Q-type calcium currents in Xenopus oocytes. Br J Pharmacol (2012) 0.84